기저 하시모토 갑상선염이 있던 유방암 환자에서 PD-1 억제제 투약 후 악화된 갑상선 종대의 증례
A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto’s Thyroiditis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Anti-programmed cell death-1 (PD-1) humanized monoclonal antibody inhibits PD-1 activity by binding to the PD-1 receptor on T-cells and blocking PD-1 ligands and induces immune tolerance of cancer cells. It has been widely used for various kinds of cancer treatment. However, many immune-related adverse events (irAEs) have been reported because it modulates our immune system. In this case study, we reported a case of 42-year-old woman with Hashimoto’s thyroiditis who showed rapid aggravation of thyroid goiter and acute hyperventilation syndrome after treatment with PD-1 inhibitor as a neoadjuvant chemotherapy for breast cancer.
Abstract
Anti-programmed cell death-1 (PD-1) humanized monoclonal antibody inhibits PD-1 activity by binding to the PD-1 receptor on T-cells and blocking PD-1 ligands and induces immune tolerance of cancer cells. It has been widely used for various kinds of cancer treatment. However, many immune-related adverse events (irAEs) have been reported because it modulates our immune system. In this case study, we reported a case of 42-year-old woman with Hashimoto’s thyroiditis who showed rapid aggravation of thyroid goiter and acute hyperventilation syndrome after treatment with PD-1 inhibitor as a neoadjuvant chemotherapy for breast cancer.
참고문헌 (15)
- Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372(21), pp.2018~2028 (2015)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PDL1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial", Lancet, 387(10027), pp.1540~1550 (2016)
- Langer CJ, "Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study", Lancet Oncol, 17(11), pp.1497~1508 (2016)
- Chen R, "Phase II study of the efficacy and safety of pembrolizumab for relapsed", refractory classic Hodgkin lymphoma, 2017, pp.35(19), 2125~2132
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366(26), pp.2443~2454 (2012)
- Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma", N Engl J Med, 372(26), pp.2521~2532 (2015)
- de Filette J, "Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab", J Clin Endocrinol Metab, 101(11), pp.4431~4439 (2016)
- Delivanis DA, "Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms", J Clin Endocrinol Metab, 102(8), pp.2770~2780 (2017)
- Orlov S, "Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies", J Clin Endocrinol Metab, 100(5), pp.1738~1741 (2015)
- Hashimoto H, "Zur Kenntnis der lymphomatösen Veränderung der Schilddrüse (Struma lymphomatosa)", Arch Klin Chir, 97, pp.219~248 (1912)
- Rapoport B, "Pathophysiology of Hashimoto's thyroiditis and hypothyroidism", Annu Rev Med, 42, pp.91~96 (1991)
- Huber G, "Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies", J Clin Endocrinol Metab, 87(7), pp.3221~3226 (2002)
- Rieu M, "Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre", Clin Endocrinol (Oxf), 39(1), pp.67~71 (1993)
- Ribas A, "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial", Lancet Oncol, 16(8), pp.908~918 (2015)
- Guaraldi F, "Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution", J Endocrinol Invest, 41(5), pp.549~556 (2018)